SIERRA ONCOLOGY Revenue, Profits - SRRA Quarterly Income Statement

Add to My Stocks
$1.94 $0.07 (3.74%) SRRA stock closing price Sep 20, 2018 (Closing)

Looking at financial statements, along with the SIERRA ONCOLOGY stock price, it's management, its economic moat, and industry competitors forms an important part of fundamental analysis. In the income statement, an investor can look at important parameters like revenue or sales, gross profits, net profits, and EPS basic to gain deeper insights. When compared with the corresponding income statement from the past, the latest income statement shows how revenue has decreased from - to - and how operating and non operating activities have impacted the SRRA stock. The operating expenses as shown in the SIERRA ONCOLOGY profit and loss statement for 2018 Q2 total to $12.97M. This line item shows that the operating expenses has increased compared with last year. Also check: SIERRA ONCOLOGY assets and SIERRA ONCOLOGY free cash flow.

View and download details of revenue and profits for SIERRA ONCOLOGY for latest & last 40 quarters.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
SIERRA ONCOLOGY Revenues or Net Sales
Cost Of Goods Sold (COGS)----------
Research & Development Expense8.79M8.33M7.56M7.4M7.19M8M-28.06M12.32M9.11M6.63M
Selling General & Admin Expense4.18M3.42M3.27M2.77M3.28M3.14M-10.76M2.96M3.83M3.97M
Income Before Depreciation Depletion Amortization-12.96M-11.75M-10.81M-10.18M-10.47M-11.15M38.83M-15.28M-12.94M-10.61M
Depreciation Depletion Amortization----------
Non Operating Income-------0.24M---
Interest Expense----------
Provision for Income Taxes-0.42M------0.03M---
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-11.96M-11.53M-10.6M-10M-10.33M-11.09M-9.25M-15.21M-12.87M-10.54M
Extraordinary Items & Discontinued Operations----------
SIERRA ONCOLOGY Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS74.32M59.72M52.33M52.27M52.27M42.6M30.37M30.33M30.19M30.07M
Average Shares used to compute Basic EPS74.32M59.72M52.33M52.27M52.27M42.6M30.37M30.33M30.19M30.07M
Income Before Nonrecurring Items-11.96M-11.53M-10.6M-10M-10.33M-11.09M-9.25M-15.21M-12.87M-10.54M
Income from Nonrecurring Items----------
SIERRA ONCOLOGY Earnings Per Share Basic Net
SIERRA ONCOLOGY Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items-0.16-0.19-0.20-0.19-0.20-0.26-0.30-0.50-0.43-0.35
Preferred Dividends Acc Pd----------
Dividends Common0.000.000.00-------
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Before investing one should read a report on SIERRA ONCOLOGY stock analysis. It helps to look at the following income statement items:

  • Topline: A growing topline, as seen from the SIERRA ONCOLOGY revenue chart, as isn't the case with SIERRA ONCOLOGY indicates a sagging business. One needs to compare the QoQ topline or sales growth of SRRA stock with its peers like FWP stock and CYDY stock to see if the growth compares well with what can be expected from a company in that industry.
  • Bottom line: The word bottom line comes because it is usually the last line of the income statement and refers to the actual profits after deducting all expenses from the revenues. SRRA stock had a poor bottom line growth.

The income statement is also called statement of revenue and expense. The SRRA financials along with SIERRA ONCOLOGY historical stock prices provide a lot of details about the firm.

SIERRA ONCOLOGY Income Statement - Key Financial Ratios